• APS, SPR and APA members may attend the ASPHO Meeting at no additional fee only if they are registered with PAS. 
• ASPHO members may attend the PAS Annual Meeting at no additional fee only if they are registered with ASPHO. 
• All others will be required to pay the registration fee assessed by ASPHO in addition to the PAS registration fee. 

• Register  for PAS online now!
• Print PAS Paper Registration Form

• Register  for the ASPHO Annual Meeting

Wyndham Baltimore Inner Harbor
101 West Fayette Street
Baltimore, MD 21201
888/849-1723 (reservations)

Make your reservations EARLY to ensure that you obtain the special room rates. You must mention that you are attending the ASPH/O meeting. The reservation cutoff date is April 2, 2002. All reservations require a deposit equal to 1 night's stay. Such deposit shall serve to confirm the reservation for the date(s) indicated, and, upon check-in, shall be applied to the first night of the reserved stay. All major credit cards are accepted. Deposits are refundable with a 2-day prior-to-arrival notice and after cancellation number is obtained.

To secure lodging, call the ASPHO housing bureau at 888-849-1723 or make your reservation online by April 2, 2002:

• Make an ASPHO Hotel Reservation online now!

American Society of Pediatric Hematology/Oncology
4700 W. Lake
Glenview, Il 60025-1485
Phone: 847-375-4716 
Fax: 877-734-9557
E-Mail: info@aspho.org
URL: www.aspho.org

The 15th Annual Meeting of The American Society of Pediatric Hematology/Oncology will present current data from research concerning causes, diagnosis, and management of hematology/oncology problems in children and will apply it to clinical practice.  

Conference Objectives

• Discuss mechanisms for neonatal iron overload and explore genetic causes for hereditary hemochromatosis.

• Evaluate the new approaches to pediatric Hodgkin’s Disease.

• Examine the principles underlying current approaches to infant brain tumors, including coordinated use of stereotactic neurosurgery, variable levels and durations of chemotherapy, and conformal radiation therapy.

• Define the laboratory and clinical features of TTP and HUS and develop an evidence-based treatment strategy for these patients.

• Assemble a network of professional colleagues with whom to solve problems, share experiences, and provide mutual professional support.

Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati College of Medicine and ASPHO. The University of Cincinnati College of Medicine is accredited by ACCME to provide continuing medical education (CME) for physicians.

The University of Cincinnati College of Medicine designates this CME activity for a maximum of 16 hours in Category 1 credit toward the American Medical Association Physician’s Recognition Award. Each physician should claim only those hours of credit he or she actually spent in the educational activity.

All faculty are required to disclose to program participants any relationship, including financial interest or affiliation (s) with a commercial company, as well as discussion of unlabeled uses. Full disclosure of faculty relationships will be made available to program participants by verbal and/or written statements prior to the activity.

The material presented at this meeting represents the opinion of the speakers and not necessarily the views of the University of Cincinnati College of Medicine or ASPHO.

NOTE: 
ASPHO Programming on Thursday and Friday 
is at the Wyndham Inner Harbor Hotel

Visit the 
ASPHO web site 
for further information on its programs.

Visit the 
ASPHO web site 
for further information on its programs.

Visit the 
ASPHO web site 
for further information on its programs.

Visit the 
ASPHO web site 
for further information on its programs.

Thursday, May 2, 2002 (at Wyndham Inner Harbor Hotel)
7:00am – 8:00am
Pediatric Cancer Workshop (301)
Jeffrey Moscow, University of Kentucky Medical Center, Lexington, KY
Peter Adamson, Children’s Hospital of Philadelphia, Philadelphia, PA

7:00am – 8:00am
Bone Marrow Failure Workshop (302)
Jeffrey Hord, Children’s Hospital Medical Center, Akron, OH
Adrianna Vlachos, Schneider Children’s Hospital, New Hyde Park, NY

8:15am – 9:00am
Telling the Story of Childhood Cancer Victims: How to Make Legislators Listen and Act
Keynote Address
Congressional Representative Deborah Pryce (R-OH), Founder, Hope Street Kids

9:00am – 11:30am
Iron Metabolism in Health and Disease (101)

This symposium will concentrate on the clinical importance for the practicing pediatric hematologist and oncologist of our new understanding of the molecular and cellular bases of iron metabolism, with an emphasis on the diagnosis and treatment of iron overload in infants, children and adolescents. The remarkable progress that has been made in identifying the genes and proteins involved in the absorption, transport, utilization and storage of iron will first be summarized. The next focus of discussion will be on the heterogenous group of disorders known as "neonatal hemochromatosis" and current understanding of their management. The symposium will then consider the best therapeutic strategies for the iron overload that develops in patients who require red blood cell transfusions chronically, including those with thalassemia major, Blackfan-Diamond syndrome, aplastic anemia and other refractory anemias, and, increasingly, sickle cell disorders. Finally, the symposium will examine hereditary hemochromatosis and other forms of primary iron overload, including juvenile hemochromatosis, especially the usefulness of genotypic and phenotypic approaches in screening and diagnosis and current recommendations with respect to the need for treatment. The overall goal of the symposium will be the integration of new information about iron metabolism into the clinical practice of pediatric hematology and oncology.

Introduction
Gary Brittenham, Columbia University, New York, NY
New Developments in Iron Metabolism
Nancy Andrews, Howard Hughes Medical Institute, Boston, MA
Neonatal Homochromatosis
Sujit Sheth, Columbia University College of Physicians and Surgeons
Transfusional Iron Overload
Nancy Olivieri, Hospital for Sick Children, Toronto, ON Canada
Hereditary Hemochromatosis and Other Primary iron Overload Conditions
Gary Brittenham, Columbia University, New York, NY

10:00am – 10:30am
Coffee Break

11:30am – 12:30pm
Pediatric Hematology/Oncology: A Look into the Future (108)
Frank A. Oski Memorial Lecture
George Dover, Johns Hopkins Hospital, Baltimore, MD

12:30pm – 2:30pm
From Anti-coagulation to Coagulation Therapy: Issues Specific to the Pediatric Patient (105)
Luncheon Symposium

2:30pm – 3:00pm
Dessert Break with Exhibits

3:00pm – 5:00pm
Novel Strategies for Lymphoma in Children (102)

This symposium will review new initiatives in the treatment of lymphoma. Newer approaches to pediatric Hodgkin’s disease are emerging, with an emphasis on response tailored, time intensive regimens to improve efficacy and to reduce toxicity. Understanding of the biology of this disease may lead to novel, less toxic approaches that will be discussed. The role of EBV in the pathogenesis of Hodgkin’s disease and PTLD will be addressed with consideration of potential immunologic methods of treating EBV positive tumors and PTLD. Options for treatment of recurrent NHL, particularly the role of radioisotopes and stem cell transplantation, will be the focus of the third presentation.

Introduction
Cindy Schwartz, Johns Hopkins Hospital, Baltimore, MD
Targeting EBV in Tumors and Lymphoproliferative Disorders
Richard Ambinder, Johns Hopkins Hospital, Baltimore, MD
New Approaches for the Treatment of Hodgkin's Disease
Cindy Schwartz, Johns Hopkins Hospital, Baltimore, MD
Treatment Strategies for Recurrent Non-Hodgkin's Lymphoma
Timothy Griffin, Cook Children’s Medical Center, Fort Worth, TX

5:00pm – 6:30pm
Grand Opening Reception with Exhibits

Friday, May 3, 2002 (at Wyndham Inner Harbor Hotel)
7:15am – 8:15am
Immune Thrombocytopenia Workshop (303)
Victor Blanchette, University of Toronto, Toronto, ON Canada
Thomas Kuehne, University Children’s Hospital, Basel, Switzerland

7:15am – 8:15am
Thrombotic Disorders Workshop (304)
Lori Luchtman-Jones, Washington University School of Medicine, St. Louis, MO
Patricia Massicotte, University of Toronto, Toronto, ON, Canada

8:30am – 10:30am
Pediatric Brain Tumors—Current Approaches to Dose Intensification (103)

Amongst the major challenges in pediatric brain tumors are ongoing investigations in chemotherapy and radiation therapy delivery. This symposium will address high-dose chemotherapy in two settings: high-dose chemotherapy as primary or salvage treatment for malignant gliomas, and the feasibility and early results of tandem stem-cell supported administrations following craniospinal irradiation for embryonal CNS tumors. The integration of chemotherapy and conformal radiation delivery is an equally challenging and timely issue in infants and young children with CNS tumors.

Introduction
Larry Kun, St. Jude Children’s Research Hospital, Memphis, TN
High Dose Chemotherapy in the Primary Management of Malignant Gliomas
Sharon Gardner, New York University School of Medicine, New York, NY
Repeated High Dose Chemotherapy Following Craniospinal Irradiation in Embryonal CNS Tumors
Amar Gajjar, St. Jude Children’s Research Hospital, Memphis, TN
Contemporary Directions in the Management of Malignant Brain Tumors in Infants
Larry Kun, St. Jude Children’s Research Hospital, Memphis, TN

10:30am – 11:00am
Break with Exhibits

11:00am – 12:00pm
Young Investigator's Workshop (201)
Judith Margolin, Texas Children’s Cancer Center, Houston, TX
John Maris, Children’s Hospital of Pennsylvania, Philadelphia, PA

Practice Management Workshop (202)
John Hutter, Jr., Arizona Health Sciences Center, Tucson, AZ
Jeffrey Moscow, University of Kentucky Medical Center, Lexington, KY

Hereditary Bleeding Disorders Workshop (305)
Pedro de Alarcon, University of Virginia, Charlottesville, VA
Marilyn Manco-Johnson, Mountain States Regional Hemophilia Center, Aurora, CO

12:00pm – 2:00pm
Novel Cytokines for Hematologic Support (107)
Luncheon Symposium

2:00pm – 4:30pm
Presidential Symposium
Update on Acquired Hemorrhagic and Thrombotic Disorders During Childhood (104)

This year the Presidential Symposium will deal with acquired hemorrhagic and thrombotic disorders during childhood. Among the topics to be covered are thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, with one of the world’s experts offering an update about these interesting and perplexing conditions, a review of the pathophysiology, diagnosis, and management of lupus anticoagulants, and an overview of bleeding and clotting complications encountered in critically ill patients which often result in a hematology-oncology consultation.

Introduction
George Buchanan, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome: Experience with Adults and Implications for Children
James George, University of Oklahoma, Oklahoma City, OK
Lupus Anticoagulants
Eric Grabowski, Massachusetts General Hospital, Boston, MA
Critical Care Clotting Catastrophes
Thomas DeLoughery, Oregon Health Sciences Center, Portland, OR

3:15pm – 3:45pm
Coffee Break

4:30pm – 5:00pm
Distinguished Career Award Presentation

5:00pm – 5:30pm
Business Meeting

5:30pm – 6:00pm
Distinguished Career Award Reception

Saturday, May 4, 2002 
(at Wyndham Inner Harbor Hotel)
7:30am – 8:30am
Hemoglobinopathy Workshop (306)
Peter Lane, University of Colorado, Denver, CO
Russell Ware, Duke University Medical Center, Durham, NC

Histiocyte Workshop (307)
Kenneth McClain, Texas Children’s Hospital, Houston, TX
Jan-Inge Henter, British Columbia Children’s Hospital, Vancouver, BC, Canada

 (Programming Begins at Baltimore Convention Center)

9:15am – 12:00pm
PAS/ASPHO Mini Course:
Long-Term Effects of Childhood Cancer
Chair: Smita Bhatia, City of Hope National Medical Center, Duarte, CA

This mini-course will address several of the major topics of interest relating to the long-term health status and psychosocial functioning of individuals diagnosed and treated for cancer during childhood and adolescence. Topics to be presented include endocrinologic sequelae, risk of subsequent malignancies, psychosocial late-effects, and educational/intervention strategies.

Second and Subsequent Malignancies Among Survivors of Childhood Cancer
Smita Bhatia, City of Hope National Medical Center, Duarte, CA
Endocrinologic Late Effect Among Survivors of Childhood and Adolescent Cancers
Charles A. Sklar, Memorial Sloan-Kettering Cancer Center, New York, NY
Educational Intervention Strategies Among Childhood Cancer Survivors
Melissa Hudson, St. Jude Children’s Research Hospital, Memphis, TN
Psychosocial Function of Childhood Cancer Survivors
Daniel Armstrong, University of Miami School of Medicine, Miami, FL

9:15am – 12:00pm
PAS/ASPHO Mini Course:
Long-Term Effects of Childhood Cancer
Chair: Nancy Bunin, Children’s Hospital of Philadelphia, Philadelphia, PA

This minicourse will provide participants with an update on both the current status and future of stem cell transplant in pediatrics. Both malignant and non-malignant diseases will be addressed. Advances in graft engineering have made many of these advances possible, and this will be discussed in an overview of autologous stem cell transplant for solid tumors. Allogeneic stem cell transplant may be curative for some patients with hemoglobinopathies and metabolic diseases. Non-myeloablative approaches to hemoglobinopathies are a relatively novel approach, which may be curative without some of the short and long-term toxicities of a myeloablative regimen. Disease-specific characteristics that impact upon transplant outcome of patients with inherited metabolic storage disorders will be identified and discussed. Finally, the concepts of mesenchymal cell transplant and the future of mesenchymal cell transplant therapy will be summarized and discussed.

Tandem Transplantation for High-Risk Pediatric Malignancies
Stephen Grupp,The Children’s Hospital of Philadelphia, Philadelphia, PA
Reducing the Toxicity of Stem Cell Transplantation for Hemoglobinopathies
Robert Iannone, The Children’s Hospital of Philadelphia, Philadelphia, PA
Stem Cell Transplantation for Selected Inherited Metabolic Disease: The Mucopolysaccharidoses and the Leukodystrophies
Charles Peters, University of Minnesota Medical School, Minneapolis, MN
Future Horizons in Stem Cell Transplantation: The Quest to Conquer Non-Hematopoietic Disease
Edwin Horwitz, St. Jude Children’s Research Hospital, Memphis, TN

10:00am – 12:00pm
PAS Educational Seminars

9:15am – 12:00pm
PAS/ASPHO Mini Course:
The New Pediatrics in the Genomic Era
Chair: Isaac Kohane, Lyle Palmer, and Scott Pomeroy, Children’s Hospital, Boston, MA

The sequencing of the human genome and the availability of large scale genomic measurement technologies will change the manner in which clinical care and pediatric research is conducted. We will address how these genomic technologies, bioinformatics and genetic epidemiology can be applied in these endeavors.

Extracting Biomedical Knowledge from Genomic Data
Isaac S. Kohane, Children’s Hospital, Boston, MA
Genomic Approaches to Elucidating Tumorigenesis
Scott Pomeroy, Children’s Hospital, Boston, MA
A Population Approach to Genomics
Lyle Palmer, Harvard Medical School, Boston, MA

1:00pm – 3:00pm
PAS Educational Seminars

1:00pm – 3:00pm
Hematology/Oncology Platform I
PAS/ASPHO Original Science Abstracts
(Abstract session information will be posted in mid-February)

3:15pm – 5:15pm
PAS/ASPHO Topic Symposium:
Stroke in Childhood
Chair: Donna Ferriero, University of California, San Francisco. CA

This session will update physicians on epidemiology and risk factors for perinatal and childhood stroke. Emphasis will be placed on identifying risk factors, increasing recognition, and providing possibilities for treatment.

Biologic Mechanisms of Stroke
Valina Dawson, Johns Hopkins University, Baltimore, MD
Childhood Stroke
Gabrielle deVeber, Hospital for Sick Children, Toronto, Canada
Imaging in Childhood Stroke
Linda deVries, Wilhelmina Children’s Hospital, UMCU, The Netherlands
Epidemiology of Perinatal Stroke
Karin Nelson, National Institute of Health, Bethesda, MD

3:15pm – 5:15pm
PAS/ASPHO Topic Symposium:
Cloning and Embryonic Stem Cells
Chair: Judith Hall, University of British Columbia, Vancouver, Canada

There is enormous public interest in cloning and embryonic stem cells. This symposium will update the pediatric community on recent developments and raises a variety of policy and ethical issues.

Cloning
Brigid Hogan, Vanderbilt University Medical Center, Nashville, TN
Imprinting and Reprogramming
Arthur L. Beaudet, Baylor College of Medicine, Houston, TX
Embryonic Stem Cells
Janet Rossant, University of Toronto, On, Canada

5:15pm – 7:15pm
Poster Session I, PAS Opening Reception & Exhibits
Hematology/Oncology Poster I
PAS/ASPHO Original Science Abstracts 
(Abstract session information will be posted in mid-February)

Sunday, May 5, 2002 (at Baltimore Convention Center)
8:00am – 10:00am
Hematology/Oncology Platform II
PAS/ASPHO Original Science Abstracts
(Abstract session information will be posted in mid-February)

11:45am – 1:45pm
Poster Session II
PAS/ASPHO Original Science Abstracts
(Abstract session information will be posted in mid-February)

2:00pm – 4:00pm
PAS/ASPN/ASPHO Topic Symposium:
Cancer, Blood, and the Kidney: Common Themes
Chairs: Ellis D. Avner, President, American Society of Pediatric Nephrology and George R. Buchanan, President, American Society of Pediatric Hematology/Oncology

Many children with cancer, hematological disorders, or kidney disease have complex, multisystem problems. Advances in cell and molecular biology provide insights into the interrelationships of cancer, blood, and the kidney and have led to new diagnostic and therapeutic approaches for the clinician. Such approaches are reviewed in this symposium which focuses specifically on the nephrological complications of sickle cell anemia and bone marrow transplantation, hematological complications of nephrotic syndrome, and the molecular pathophysiology of WT-1 associated disorders.

Sickle Cell Nephropathy: Pathophysiology and Therapy
Jon Scheinman, University of Kansas Medical Center, Kansas City, KS
Thromboembolic Complications of the Nephrotic Syndrome
M. Patricia Massicotte, University of Toronto, Hospital for Sick Children, Toronto, ON, Canada
Renal Complications of Bone Marrow Transplantation
Ruth McDonald, Univ of Washington/Children’s Hosp & Reg Med Ctr, Seattle, WA
Molecular Pathophysiology of Wilm's Tumor and Denys-Drash/Frasier Syndromes
Max J. Coppes, Alberta Children’s Hosp, Children’s Cancer Program, Calgary, AB, Canada

Sponsored jointly with the American Society of Pediatric Hematology/Oncology, the American Society of Pediatric Nephrology and the Pediatric Academic Societies

2:00pm – 4:00pm
PAS State of the Art Plenary:
Children as Research Subjects: Ethical and Regulatory Issues
Chair: Myron Genel, Yale University School of Medicine, New Haven, CT

A number of highly publicized adverse events, including the death of two volunteers participating in non-therapeutic research, and the federal shutdown of research at many well recognized academic institutions because of inadequate compliance with regulatory requirements have intensified scrutiny of the protection afforded to human subjects participating in research, including children. Furthermore a Maryland court has recently decreed that children cannot participate in research without the potential for direct benefit. As a consequence there has been increasing media attention and Congressional concern regarding the adequacy of institutional oversight and investigator attentiveness to established standards and regulations. In addition, new regulations issued under the Health Insurance Portability and Accountability Act of l996 (HIPAA) threaten the capacity to conduct health services and outcomes research. These issues will be addressed in the 9th annual Public Policy Plenary Symposium in an interactive format intended to stimulate dialogue among the members of the panel and with the audience.

Overseeing Research in Children: New Concerns and New Regulations
Alan R. Fleischman, The New York Academy of Medicine, New York, NY
International Health Research: Where Bioethics, Politics and Economics Converge
Eric Meslin, Indiana University School of Medicine, Indianapolis, IN
Compliance: What You and Your Institution Need To Know (and Do)
Patricia Pearl O’Rourke, Partners HealthCare Systems, Inc., Boston, MA
HIPAA, Privacy and Confidentiality and Research in Children?
Sara Rosenbaum, George Washington University, Washington, DC

Sponsored jointly with the Public Policy Council of the APS, AMSPDC, SPR and the Public Policy Committee of the APA

2:30pm – 4:00pm
PAS State of the Art Plenary:
Developmental Biology and Pediatrics
Chair: David H. Rowitch, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Basic studies of developmental biology can have profound implications for child health and disease. In this State of the Art Plenary, pediatric investigators at the forefront of basic science will describe recent advances in our understanding of development of the central nervous system, heart and blood with implications for the pathophysiology of congenital malformations, acquired disease and pediatric cancer.

Hedgehog Signaling in CNS Development and Tumorigenesis
David H. Rowitch, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
Molecular Pathways of Cardiac Development and Congenital Heart Disease
Deepak Srivastava, The University of Texas Southwestern Medical Center, Dallas, TX
Molecular Control of Hematopoietic Cell
Stuart H. Orkin, Harvard Medical School, Children’s Hospital Medical Center, Boston, MA

2:30pm – 4:00pm
PAS State of the Art Plenary:
Pediatric Research and the DNA Sequence: Approaching Defects of Host Defenses in the Genomic Era
Chairs: Jennifer M. Puck, National Human Genome Research Institute, National Institute of Health, Bethesda, MD and Stephen J. Chanock, National Cancer Institute, National Institute of Health, Bethesda, MD

This session will provide a framework for understanding how genetics and genomics can accelerate progress in understanding defects in immunity and host defenses. Host defenses are used to demonstrate the general power of these technologies to elucidate pathogenetic mechanisms and predict disease susceptibility. This program will address classical and novel approaches to discovering genes underlying primary immunodeficiencies as well as characterization of modifier genes. A brief overview of the human genome, its structure, contents and relationship to genomes of other species will be presented in order to discuss current and future potential for understanding pediatric diseases and treatments. Emphasis will be placed on the continued prime importance of careful clinical observation, as well as the ethical and practical issues that genome science presents to society.

Finding a Multitude of Disease Genes for Primary Immune Disorders
Jennifer M. Puck, National Human Genome Research Institute/National Institute of Health, Bethesda, MD
The Role of Variation in the Human Genome: Single Nucleotide Polymorphisms and Disease Modifiers
Stephen J. Chanock, National Cancer Institute, National Institute of Health, Bethesda, MD
Applications of Genomic Technology to Understanding Human Phenotypes
Aravinda Chakravarti, Johns Hopkins University School of Medicine, Baltimore, MD

4:15pm – 6:15pm
PAS/ASPHO Topic Symposium:
End-of-Life Palliative Care
Chair: Marcia Levetown, Independent Pain and Palliative Care Consultant, Houston, TX

53,000 children die annually in the United States and many more live with chronic, life-threatening conditions. Yet, pediatric education and subspecialty training do not currently prepare practitioners to care for these needy children, their parents, community and survivors. This symposium, presented by a pediatric hematologist/oncologist, pediatric palliative care physician and a bereaved parent, will discuss how to incorporate palliative care into pediatric care. Specific highlights are the presentation of an integrated model of care, beginning at the time of diagnosis of a potentially life-threatening condition, parental and patient perspectives on the fight against disabling symptoms and death, and the ethics behind the decision-making process that confronts the family and medical care team.

Incorporating Pediatric Palliative Care Principles into Oncology Care from the Time of Diagnosis
Joanne Hilden, The Cleveland Clinic Foundation, Cleveland, OH
The Value of a Day in the Life of a Terminally Ill Child
Jan Wheeler, University of Houston, Houston, TX, Bereaved Mother
Ethical Issues in Medical Decision-Making: When the Patient Is a Child
Marcia Levetown, Independent Pain and Palliative Care Consultant, Houston, TX

Tuesday, May 7, 2002 (PAS Programs that may be of interest)
10:00am – 11:45am
PAS State of the Art Plenary:
Pediatric Pain

10:00am – 11:45am
PAS State of the Art Plenary:
Regenerative Medicine—From Stem Cells to Tissues

10:15am – 11:45am
PAS State of the Art Plenary:
Pharmacogenomics: Clinical and Therapeutic Implications